Rebecca C. Painter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebecca C. Painter has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
Tessa J. Roseboom
Department of Obstetrics and Gynecology Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam Amsterdam the Netherlands
8 shared publications- Tessa J. Roseboom
Department of Epidemiology & Data Science, University of Amsterdam, Amsterdam, the Netherlands
8 shared publications - Ben Willem Mol
Department of Obstetrics and Gynaecology Monash University Clayton Victoria Australia
6 shared publications - Clive Osmond
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
6 shared publications T.J. Roseboom
5 shared publicationsDavid J Barker
3 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Oral Antihyperglycemic Agents Versus Insulin for Gestational Diabetes Mellitus: Societal Cost‐Effectiveness Analysis of the SUGAR ‐ DIP Randomized Controlled Trial
Objective: To assess the cost‐effectiveness of treatment with sequential oral antihyperglycemic agents (OHA; metformin and glibenclamide) versus insulin for gestational diabetes (GDM). Design: Cost‐effectiveness analysis from a societal and healthcare perspective alongside a randomized controlled trial (SUGAR‐DIP). Setting: Twenty‐five hospitals in the Netherlands. Population: Women with GDM and a singleton pregnancy, randomized to OHA ( n = 409) or insulin ( n = 411) between 16 to 34 weeks' gestation. Methods: Missing data were handled using multiple imputation. Differences in costs and effects were estimated using bivariate regression with bootstrapping to derive incremental cost‐effectiveness ratios. Cost‐effectiveness acceptability curves were constructed across a range of willingness‐to‐pay (WTP) thresholds. Main Outcome Measures: Large for gestational age (LGA), quality‐adjusted life‐years (QALYs), costs and cost‐effectiveness. Results: OHA slightly increased QALYs (0.009; 95% CI 0.004 to 0.014), corresponding to approximately 3 days in perfect health. There were no statistically significant differences in LGA avoided (−0.039; 95% CI−0.097 to 0.018) or societal costs (mean difference−€1004; 95% CI−€3503 to €1495). OHA were less costly and less effective than insulin for LGA, whereas for QALYs they were less costly and more effective. The probability of OHA being cost‐effective at a WTP threshold of €0 was 79% for both outcomes. Conclusions: OHA have a high probability of being cost‐effective compared with insulin for QALYs, although the QALY gain is small and of limited clinical relevance. For LGA, OHA were less costly but less effective, and cost‐effectiveness depends on acceptable trade‐offs between costs and neonatal outcomes.
- 25 October 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Open AccessOral Antihyperglycemic Agents Versus Insulin for Gestational Diabetes Mellitus: Societal Cost‐Effectiveness Analysis of the SUGAR ‐ DIP Randomized Controlled Trial
Objective: To assess the cost‐effectiveness of treatment with sequential oral antihyperglycemic agents (OHA; metformin and glibenclamide) versus insulin for gestational diabetes (GDM). Design: Cost‐effectiveness analysis from a societal and healthcare perspective alongside a randomized controlled trial (SUGAR‐DIP). Setting: Twenty‐five hospitals in the Netherlands. Population: Women with GDM and a singleton pregnancy, randomized to OHA ( n = 409) or insulin ( n = 411) between 16 to 34 weeks' gestation. Methods: Missing data were handled using multiple imputation. Differences in costs and effects were estimated using bivariate regression with bootstrapping to derive incremental cost‐effectiveness ratios. Cost‐effectiveness acceptability curves were constructed across a range of willingness‐to‐pay (WTP) thresholds. Main Outcome Measures: Large for gestational age (LGA), quality‐adjusted life‐years (QALYs), costs and cost‐effectiveness. Results: OHA slightly increased QALYs (0.009; 95% CI 0.004 to 0.014), corresponding to approximately 3 days in perfect health. There were no statistically significant differences in LGA avoided (−0.039; 95% CI−0.097 to 0.018) or societal costs (mean difference−€1004; 95% CI−€3503 to €1495). OHA were less costly and less effective than insulin for LGA, whereas for QALYs they were less costly and more effective. The probability of OHA being cost‐effective at a WTP threshold of €0 was 79% for both outcomes. Conclusions: OHA have a high probability of being cost‐effective compared with insulin for QALYs, although the QALY gain is small and of limited clinical relevance. For LGA, OHA were less costly but less effective, and cost‐effectiveness depends on acceptable trade‐offs between costs and neonatal outcomes.
- 12 August 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
CGM Metrics and the Risk of Pregnancy Complications in Type 1 Diabetes: A Secondary Exploratory Analysis of the CRISTAL Trial
Objective: To examine the associations between continuous glucose monitoring (CGM) metrics, including glucose management indicator (GMI) and overnight glucose levels, and pregnancy outcomes in women with type 1 diabetes. Research Design and Methods: Secondary exploratory analysis of the CRISTAL trial including 95 pregnant women with type 1 diabetes using CGM. Associations were assessed using logistic regression and Spearman correlations, presented as odds ratios (95% confidence intervals [CIs]) adjusted for baseline HbA1c. GMI validity was assessed using scatter and Bland–Altman plots. Results: Each 5% increase in overall pregnancy-specific time-in-range (TIRp) decreased the odds of gestational hypertension (odds ratio [OR] 0.63, 95% CI 0.41–0.97), birthweight >4.5 kg (OR 0.56, 95% CI 0.32–0.96), and neonatal hypoglycemia requiring hospital care (OR 0.09, 95% CI 0.01–0.57). Each 5% increase in overnight TIRp decreased the odds of gestational hypertension (OR 0.71, 95% CI 0.52–0.98) and neonatal hypoglycemia requiring hospital care (OR 0.15, 95% CI 0.03–0.79). Each 5% increase in overall time-above-range (TARp) increased the odds of birthweight >4.5 kg (OR 1.76, 95% CI 1.05–2.96), respiratory distress (OR 1.55, 95% CI 1.02–2.37), and neonatal hypoglycemia requiring hospital care (OR 5.10, 95% CI 1.14–22.78). Each 5% increase in TARp overnight increased the odds of hospital care for neonatal hypoglycemia (OR 2.55, 95% CI 1.15–5.66). Each 0.28 mmol/L increase in mean glucose and 0.5% increase in GMI were associated with increased respiratory distress (OR 1.54, 95% CI 1.07–2.23 and OR 6.15, 95% CI 1.33–28.40). Every 0.28 mmol/L increase in glycemic variability (SD) was associated with gestational hypertension (OR 1.69, 95% CI 1.02–2.80) and birthweight >4.5 kg (OR 2.31, 95% CI 1.20–4.43). Several combinations of CGM metrics (TIRp[-night], TARp[-night], SD, mean glucose) improved discriminative performance for pregnancy outcomes. GMI and HbA1c values were discordant. Conclusions: Specific combinations of CGM metrics, including overnight TIRp/TARp, may be informative for predicting pregnancy outcomes. GMI and HbA1c should not be considered interchangeable for glycemic control during pregnancy.
- 12 August 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
CGM Metrics and the Risk of Pregnancy Complications in Type 1 Diabetes: A Secondary Exploratory Analysis of the CRISTAL Trial
Objective: To examine the associations between continuous glucose monitoring (CGM) metrics, including glucose management indicator (GMI) and overnight glucose levels, and pregnancy outcomes in women with type 1 diabetes. Research Design and Methods: Secondary exploratory analysis of the CRISTAL trial including 95 pregnant women with type 1 diabetes using CGM. Associations were assessed using logistic regression and Spearman correlations, presented as odds ratios (95% confidence intervals [CIs]) adjusted for baseline HbA1c. GMI validity was assessed using scatter and Bland–Altman plots. Results: Each 5% increase in overall pregnancy-specific time-in-range (TIRp) decreased the odds of gestational hypertension (odds ratio [OR] 0.63, 95% CI 0.41–0.97), birthweight >4.5 kg (OR 0.56, 95% CI 0.32–0.96), and neonatal hypoglycemia requiring hospital care (OR 0.09, 95% CI 0.01–0.57). Each 5% increase in overnight TIRp decreased the odds of gestational hypertension (OR 0.71, 95% CI 0.52–0.98) and neonatal hypoglycemia requiring hospital care (OR 0.15, 95% CI 0.03–0.79). Each 5% increase in overall time-above-range (TARp) increased the odds of birthweight >4.5 kg (OR 1.76, 95% CI 1.05–2.96), respiratory distress (OR 1.55, 95% CI 1.02–2.37), and neonatal hypoglycemia requiring hospital care (OR 5.10, 95% CI 1.14–22.78). Each 5% increase in TARp overnight increased the odds of hospital care for neonatal hypoglycemia (OR 2.55, 95% CI 1.15–5.66). Each 0.28 mmol/L increase in mean glucose and 0.5% increase in GMI were associated with increased respiratory distress (OR 1.54, 95% CI 1.07–2.23 and OR 6.15, 95% CI 1.33–28.40). Every 0.28 mmol/L increase in glycemic variability (SD) was associated with gestational hypertension (OR 1.69, 95% CI 1.02–2.80) and birthweight >4.5 kg (OR 2.31, 95% CI 1.20–4.43). Several combinations of CGM metrics (TIRp[-night], TARp[-night], SD, mean glucose) improved discriminative performance for pregnancy outcomes. GMI and HbA1c values were discordant. Conclusions: Specific combinations of CGM metrics, including overnight TIRp/TARp, may be informative for predicting pregnancy outcomes. GMI and HbA1c should not be considered interchangeable for glycemic control during pregnancy.
- 25 June 2024
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 131 (12) , 1694-1704
Maternal death by cancer in pregnancy: A descriptive study of the International Network on Cancer, Infertility and Pregnancy
Objective: To characterise pregnant women diagnosed with primary or recurrent cancer who died during pregnancy, during delivery or within 1 year postpartum.Design: A descriptive study.Setting: The registry of the International Network on Cancer, Infertility and Pregnancy (INCIP).Population: Women diagnosed with cancer during pregnancy between 2000 and 2022.Methods: Using the INCIP registry database, we compared the characteristics of all women with cancer who died during pregnancy, delivery or within 1 year postpartum with those of all women with cancer who survived the first year postpartum.Main Outcome Measures: Maternal and tumour characteristics and obstetrical and neonatal outcomes.Results: Of the 2359 women registered in INCIP, there were 131 cases (5.6%) of maternal mortality. Lung cancer (9/14, 64.3% of all registered women with lung cancer), gastro‐oesophageal cancer (13/21, 61.9%) and acute leukaemia (17/105, 16.2%) had the highest rates of maternal mortality. Maternal mortality was associated with fewer live births compared with the control group without maternal mortality (99/131, 75.6%, vs 1952/2163, 90.0%; P < 0.001), more elective caesarean sections (64/104, 60.4%, vs 756/1836, 41.2%; P < 0.001) and a lower gestational age at (induced) delivery (34.0 vs 37.1 weeks; P < 0.001), resulting in more preterm births.Conclusions: Maternal mortality occurred in 5.6% of cancer‐in‐pregnancy cases and is associated with adverse perinatal outcomes.
- 25 June 2024
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 131 (12) , 1694-1704
Maternal death by cancer in pregnancy: A descriptive study of the International Network on Cancer, Infertility and Pregnancy
Objective: To characterise pregnant women diagnosed with primary or recurrent cancer who died during pregnancy, during delivery or within 1 year postpartum.Design: A descriptive study.Setting: The registry of the International Network on Cancer, Infertility and Pregnancy (INCIP).Population: Women diagnosed with cancer during pregnancy between 2000 and 2022.Methods: Using the INCIP registry database, we compared the characteristics of all women with cancer who died during pregnancy, delivery or within 1 year postpartum with those of all women with cancer who survived the first year postpartum.Main Outcome Measures: Maternal and tumour characteristics and obstetrical and neonatal outcomes.Results: Of the 2359 women registered in INCIP, there were 131 cases (5.6%) of maternal mortality. Lung cancer (9/14, 64.3% of all registered women with lung cancer), gastro‐oesophageal cancer (13/21, 61.9%) and acute leukaemia (17/105, 16.2%) had the highest rates of maternal mortality. Maternal mortality was associated with fewer live births compared with the control group without maternal mortality (99/131, 75.6%, vs 1952/2163, 90.0%; P < 0.001), more elective caesarean sections (64/104, 60.4%, vs 756/1836, 41.2%; P < 0.001) and a lower gestational age at (induced) delivery (34.0 vs 37.1 weeks; P < 0.001), resulting in more preterm births.Conclusions: Maternal mortality occurred in 5.6% of cancer‐in‐pregnancy cases and is associated with adverse perinatal outcomes.
- Open Access
- 8 November 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (11) , e0275236
Maternal obesity in pregnancy and children’s cardiac function and structure: A systematic review and meta-analysis of evidence from human studies
The prevalence of obesity is increasing worldwide. Experimental animal studies demonstrate that maternal obesity during pregnancy directly affects cardiac structure and function in their offspring, which could contribute to their increased cardiovascular disease (CVD) risk. Currently, a systematic overview of the available evidence regarding maternal obesity and alterations in cardiac structure and function in human offspring is lacking. We systematically searched the electronic databases Embase, MEDLINE and NARCIS from inception to June 29, 2022 including human studies comparing cardiac structure and function from fetal life onwards in offspring of women with and without obesity. The review protocol was registered with PROSPERO International Prospective Register of Systematic Reviews (identifier: CRD42019125071). Risk of bias was assessed using a modified Newcastle-Ottawa scale. Results were expressed using standardized mean differences (SMD). The search yielded 1589 unique publications, of which thirteen articles were included. Compared to offspring of women without obesity, fetuses of women with obesity had lower left ventricular strain, indicative of reduced systolic function, that persisted in infancy (SMD -2.4, 95% confidence interval (CI) -4.4 standard deviation (SD) to -0.4 SD during fetal life and SMD -1.0, 95% CI -1.6 SD to -0.3 SD in infancy). Furthermore, infants born to women with obesity had a thicker interventricular septum (SMD 0.6 SD, 95% CI 0.0 to 1.2 SD) than children born to women without obesity. In conclusion, cardiac structure and function differs between fetuses and children of women with and without obesity. Some of these differences were present in fetal life, persisted in childhood and are consistent with increased CVD risk. Long-term follow-up research is warranted, as studies in offspring of older age are lacking.
- 8 November 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (11) , e0275236
Open AccessMaternal obesity in pregnancy and children’s cardiac function and structure: A systematic review and meta-analysis of evidence from human studies
The prevalence of obesity is increasing worldwide. Experimental animal studies demonstrate that maternal obesity during pregnancy directly affects cardiac structure and function in their offspring, which could contribute to their increased cardiovascular disease (CVD) risk. Currently, a systematic overview of the available evidence regarding maternal obesity and alterations in cardiac structure and function in human offspring is lacking. We systematically searched the electronic databases Embase, MEDLINE and NARCIS from inception to June 29, 2022 including human studies comparing cardiac structure and function from fetal life onwards in offspring of women with and without obesity. The review protocol was registered with PROSPERO International Prospective Register of Systematic Reviews (identifier: CRD42019125071). Risk of bias was assessed using a modified Newcastle-Ottawa scale. Results were expressed using standardized mean differences (SMD). The search yielded 1589 unique publications, of which thirteen articles were included. Compared to offspring of women without obesity, fetuses of women with obesity had lower left ventricular strain, indicative of reduced systolic function, that persisted in infancy (SMD -2.4, 95% confidence interval (CI) -4.4 standard deviation (SD) to -0.4 SD during fetal life and SMD -1.0, 95% CI -1.6 SD to -0.3 SD in infancy). Furthermore, infants born to women with obesity had a thicker interventricular septum (SMD 0.6 SD, 95% CI 0.0 to 1.2 SD) than children born to women without obesity. In conclusion, cardiac structure and function differs between fetuses and children of women with and without obesity. Some of these differences were present in fetal life, persisted in childhood and are consistent with increased CVD risk. Long-term follow-up research is warranted, as studies in offspring of older age are lacking.
- 3 November 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 387 (18) , 1718-1721
Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes
To the Editor: In the GEMS trial, Crowther and colleagues (Aug. 18 issue)1 conclude that applying lower glycemic thresholds for the diagnosis of gestational diabetes (as advised by the World Health Organization [WHO]) doubled the number of diagnoses of this disorder without any reduction in the number of infants who were large for their gestational age. Of the 4061 pregnant women who were enrolled in the trial, 3688 (90.8%) met either the lower or higher glycemic criteria. Only 373 women in the trial were in a subgroup with results that fell between the two criteria. In this discordant group, treatment . . .
- 3 November 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 387 (18) , 1718-1721
Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes
To the Editor: In the GEMS trial, Crowther and colleagues (Aug. 18 issue)1 conclude that applying lower glycemic thresholds for the diagnosis of gestational diabetes (as advised by the World Health Organization [WHO]) doubled the number of diagnoses of this disorder without any reduction in the number of infants who were large for their gestational age. Of the 4061 pregnant women who were enrolled in the trial, 3688 (90.8%) met either the lower or higher glycemic criteria. Only 373 women in the trial were in a subgroup with results that fell between the two criteria. In this discordant group, treatment . . .
- 6 October 2022
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 35 (26) , 10314-10323
Impact of chemotherapy during pregnancy on fetal growth
Chemotherapy crosses the placenta, however, it remains unclear to what extent it affects fetal growth. The current literature suggests up to 21% of the offspring of women receiving chemotherapy are...
- 6 October 2022
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 35 (26) , 10314-10323
Impact of chemotherapy during pregnancy on fetal growth
Chemotherapy crosses the placenta, however, it remains unclear to what extent it affects fetal growth. The current literature suggests up to 21% of the offspring of women receiving chemotherapy are...
- Open Access
Long-term outcomes following antenatal exposure to low-dose aspirin: study protocol for the 4-year follow-up of the APRIL randomised controlled trial
Introduction The use of low-dose aspirin by pregnant women to prevent preterm pre-eclampsia is gradually increasing. The administration of aspirin during pregnancy improves perinatal outcome, which could translate into improved child outcome in the long term. However, antenatal exposure to aspirin could have adverse effects on child development that may manifest later in life. The aim of this follow-up study is to assess the long-term effects of antenatal exposure to low-dose aspirin compared with placebo on survival, (neuro)development, behaviour and general health at 4 years corrected age. Methods and analysis This is a follow-up study of the Dutch double-blind randomised controlled APRIL trial which assessed the effectiveness of treatment with aspirin (80 mg daily) compared with placebo for the prevention of preterm birth in women with a previous spontaneous preterm birth. Treatment was initiated before 16 weeks of gestation and continued until 36 weeks or birth. We aim to follow-up all 379 children born to women who participated in the APRIL trial and survived the neonatal period, at the corrected age of 4 years. The main outcomes are (neuro)development as assessed by the Ages and Stages Questionnaire, and behaviour as assessed by the Strength and Difficulties Questionnaire. Additional outcomes include mortality, growth and general health from birth up to 4 years, and a composite outcome including mortality, abnormal (neuro)development and problem behaviour. Analyses will be performed by intention-to-treat using a superiority design. Ethics and dissemination Institutional Review Board approval was obtained from the Medical Research Ethics Committee from Amsterdam Medical Center (no. W20 289#20.325). The results will be published in a peer-reviewed journal and presented at conferences. Trial registration number The APRIL trial (NTR5675, NL5553; EudraCT number 2015-003220-31) and the APRIL follow-up study (NL8950) are registered in the Dutch trial register. The study is funded by the Amsterdam Reproduction & Development research institute.
Open AccessLong-term outcomes following antenatal exposure to low-dose aspirin: study protocol for the 4-year follow-up of the APRIL randomised controlled trial
Introduction The use of low-dose aspirin by pregnant women to prevent preterm pre-eclampsia is gradually increasing. The administration of aspirin during pregnancy improves perinatal outcome, which could translate into improved child outcome in the long term. However, antenatal exposure to aspirin could have adverse effects on child development that may manifest later in life. The aim of this follow-up study is to assess the long-term effects of antenatal exposure to low-dose aspirin compared with placebo on survival, (neuro)development, behaviour and general health at 4 years corrected age. Methods and analysis This is a follow-up study of the Dutch double-blind randomised controlled APRIL trial which assessed the effectiveness of treatment with aspirin (80 mg daily) compared with placebo for the prevention of preterm birth in women with a previous spontaneous preterm birth. Treatment was initiated before 16 weeks of gestation and continued until 36 weeks or birth. We aim to follow-up all 379 children born to women who participated in the APRIL trial and survived the neonatal period, at the corrected age of 4 years. The main outcomes are (neuro)development as assessed by the Ages and Stages Questionnaire, and behaviour as assessed by the Strength and Difficulties Questionnaire. Additional outcomes include mortality, growth and general health from birth up to 4 years, and a composite outcome including mortality, abnormal (neuro)development and problem behaviour. Analyses will be performed by intention-to-treat using a superiority design. Ethics and dissemination Institutional Review Board approval was obtained from the Medical Research Ethics Committee from Amsterdam Medical Center (no. W20 289#20.325). The results will be published in a peer-reviewed journal and presented at conferences. Trial registration number The APRIL trial (NTR5675, NL5553; EudraCT number 2015-003220-31) and the APRIL follow-up study (NL8950) are registered in the Dutch trial register. The study is funded by the Amsterdam Reproduction & Development research institute.
- Open Access
- 21 June 2022
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 35 (25) , 10055-10063
Depression, anxiety, and post-traumatic stress disorder symptoms after hyperemesis gravidarum: a prospective cohort study
To determine the prevalence of depression, anxiety, and posttraumatic stress disorder (PTSD) years after hyperemesis gravidarum (HG) and its association with HG severity.This prospective cohort stu...
- 21 June 2022
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 35 (25) , 10055-10063
Open AccessDepression, anxiety, and post-traumatic stress disorder symptoms after hyperemesis gravidarum: a prospective cohort study
To determine the prevalence of depression, anxiety, and posttraumatic stress disorder (PTSD) years after hyperemesis gravidarum (HG) and its association with HG severity.This prospective cohort stu...
- Open Access
- 24 May 2022
- Published by Wiley in Health Science Reports
- Vol. 5 (3) , e585
Risk factors for spontaneous preterm birth among healthy nulliparous pregnant women in the Netherlands, a prospective cohort study
Introduction: Spontaneous preterm birth (sPTB) is a major contributor to neonatal morbidity and mortality worldwide. The pathophysiology of sPTB is poorly understood, in particular among nulliparous women without apparent medical or obstetric risk factors. Therefore, we aimed to identify risk factors for sPTB in healthy nulliparous women.Material and Methods: We performed a prospective cohort study. Recruitment took place from February 2014 to December 2016 in 16 community midwifery centers in the Netherlands. Eligibility criteria were: ≥18 years, no previous pregnancy >16 weeks of gestation, healthy singleton pregnancy, and antenatal booking <24 weeks of gestation. At study inclusion, participants completed a questionnaire, including details on lifestyle, work, and medical history. Cervical length was measured by vaginal ultrasound at the second‐trimester anomaly scan. Detailed information concerning pregnancy and birth was collected via antenatal charts. We calculated the adjusted odds ratio (aOR) and 95% confidence intervals (CI) for various risk factors with correction for socioeconomic status (SES) using logistic regression and Firth's correction.Results: We included 363 women of whom pregnancy outcomes were available in 349 (96.1%) participants. The cervical length measurement was available for 225 (62.0%) participants. sPTB occurred in 26 women (7.5%). SES was associated with sPTB (OR: 3.7, 95% CI: 1.6–8.5) in univariate analysis. First or second trimester vaginal bleeding (aOR: 3.6, 95% CI: 1.4–9.0) and urinary tract infection during pregnancy (aOR: 4.9, 95% CI: 1.7–13.9) were associated with sPTB in multivariate analysis.Conclusions: This prospective cohort confirms established risk factors for sPTB in nulliparous women deemed at low risk of sPTB.
- 24 May 2022
- Published by Wiley in Health Science Reports
- Vol. 5 (3) , e585
Open AccessRisk factors for spontaneous preterm birth among healthy nulliparous pregnant women in the Netherlands, a prospective cohort study
Introduction: Spontaneous preterm birth (sPTB) is a major contributor to neonatal morbidity and mortality worldwide. The pathophysiology of sPTB is poorly understood, in particular among nulliparous women without apparent medical or obstetric risk factors. Therefore, we aimed to identify risk factors for sPTB in healthy nulliparous women.Material and Methods: We performed a prospective cohort study. Recruitment took place from February 2014 to December 2016 in 16 community midwifery centers in the Netherlands. Eligibility criteria were: ≥18 years, no previous pregnancy >16 weeks of gestation, healthy singleton pregnancy, and antenatal booking <24 weeks of gestation. At study inclusion, participants completed a questionnaire, including details on lifestyle, work, and medical history. Cervical length was measured by vaginal ultrasound at the second‐trimester anomaly scan. Detailed information concerning pregnancy and birth was collected via antenatal charts. We calculated the adjusted odds ratio (aOR) and 95% confidence intervals (CI) for various risk factors with correction for socioeconomic status (SES) using logistic regression and Firth's correction.Results: We included 363 women of whom pregnancy outcomes were available in 349 (96.1%) participants. The cervical length measurement was available for 225 (62.0%) participants. sPTB occurred in 26 women (7.5%). SES was associated with sPTB (OR: 3.7, 95% CI: 1.6–8.5) in univariate analysis. First or second trimester vaginal bleeding (aOR: 3.6, 95% CI: 1.4–9.0) and urinary tract infection during pregnancy (aOR: 4.9, 95% CI: 1.7–13.9) were associated with sPTB in multivariate analysis.Conclusions: This prospective cohort confirms established risk factors for sPTB in nulliparous women deemed at low risk of sPTB.
- Open Access
- 24 January 2022
- Published by Springer Nature in Microbiome
- Vol. 10 (1) , 1-11
Enhanced IgA coating of bacteria in women with Lactobacillus crispatus-dominated vaginal microbiota
Background: Immunoglobulin A (IgA) plays an important role in maintaining a healthy intestinal microbiome, but little is known about the interaction between local immunoglobulins and the vaginal microbiome. We assessed immunoglobulins (unbound and bound to bacteria), their association with vaginal microbiota composition and the changes over time in 25 healthy women of reproductive age. Results: In both Lactobacillus crispatus-dominated and non-L. crispatus-dominated microbiota, IgA and IgG (unbound and bound to bacteria) were higher during menses (T = 1) compared to day 7‑11 (T = 2) and day 17‑25 (T = 3) after menses onset. The majority of vaginal bacteria are coated with IgA and/or IgG. Women with L. crispatus-dominated microbiota have increased IgA coating of vaginal bacteria compared to women with other microbiota compositions, but contained less IgA per bacterium. Presence of a dominantly IgA-coated population at T = 2 and/or T = 3 was also strongly associated with L. crispatus-dominated microbiota. In women with non-L. crispatus-dominated microbiota, more bacteria were uncoated. Unbound IgA, unbound IgG, and bound IgG levels were not associated with microbiota composition. Conclusions: In conclusion, L. crispatus-dominated vaginal microbiota have higher levels of bacterial IgA coating compared to non-L. crispatus-dominated vaginal microbiota. Similar to its regulating function in the intestinal tract, we hypothesize that IgA is involved in maintaining L. crispatus-dominated microbiota in the female genital tract. This may play a role in L. crispatus-associated health benefits.
- 24 January 2022
- Published by Springer Nature in Microbiome
- Vol. 10 (1) , 1-11
Open AccessEnhanced IgA coating of bacteria in women with Lactobacillus crispatus-dominated vaginal microbiota
Background: Immunoglobulin A (IgA) plays an important role in maintaining a healthy intestinal microbiome, but little is known about the interaction between local immunoglobulins and the vaginal microbiome. We assessed immunoglobulins (unbound and bound to bacteria), their association with vaginal microbiota composition and the changes over time in 25 healthy women of reproductive age. Results: In both Lactobacillus crispatus-dominated and non-L. crispatus-dominated microbiota, IgA and IgG (unbound and bound to bacteria) were higher during menses (T = 1) compared to day 7‑11 (T = 2) and day 17‑25 (T = 3) after menses onset. The majority of vaginal bacteria are coated with IgA and/or IgG. Women with L. crispatus-dominated microbiota have increased IgA coating of vaginal bacteria compared to women with other microbiota compositions, but contained less IgA per bacterium. Presence of a dominantly IgA-coated population at T = 2 and/or T = 3 was also strongly associated with L. crispatus-dominated microbiota. In women with non-L. crispatus-dominated microbiota, more bacteria were uncoated. Unbound IgA, unbound IgG, and bound IgG levels were not associated with microbiota composition. Conclusions: In conclusion, L. crispatus-dominated vaginal microbiota have higher levels of bacterial IgA coating compared to non-L. crispatus-dominated vaginal microbiota. Similar to its regulating function in the intestinal tract, we hypothesize that IgA is involved in maintaining L. crispatus-dominated microbiota in the female genital tract. This may play a role in L. crispatus-associated health benefits.